Taken together, our data demonstrate the importance of SGK1 as molecular target in cancer therapy and the effectiveness of the SI113-dependent SGK1 inhibition also in GBM treatment, where this drug appears effective as a single agent and also in combination with radiotherapy. The gene discussed is SGK1; the disease is cancer.